Paper Details

  1. Home
  2. Paper Details

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.

Author: BernaolaEnrique, DelgadoAlfonso, Diez-DomingoJavier, EminiEmilio A, GiardinaPeter C, Gimenez-SanchezFrancisco, GruberWilliam C, GurtmanAlejandra, Infante-MarquezPilar, LiangJohn Z, Martinon-TorresFederico, Pineda-SolasValentin, ScottDaniel A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 3 randomized controlled trial compared 13-valent pneumococcal conjugate vaccine (PCV13) to 7-valent PCV (PCV7) for their effect on the immunogenicity of concomitantly administered meningococcal group C conjugated to diphtheria toxin cross-reactive material 197 (MnCCV-CRM197). PCV13 elicited substantial antipneumococcal responses against all 13 serotypes. Immunogenicity of MnCCV-CRM197 was similar between the PCV13 and PCV7 groups, with a comparable proportion of infants achieving protective MenC antibody titers.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Given the concurrent administration of multiple vaccines during routine pediatric immunizations, efforts to elucidate the potential interference of any vaccine on the immune response to the concomitantly administered antigens are fundamental to prelicensure clinical research. METHODS: T...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2013.06.049

データ提供：米国国立医学図書館（NLM）

Evaluating the Safety and Efficacy of Vaccines for Little Ones

The world of vaccines is an exciting one, particularly for those of us who have a fondness for little ones. This study investigates the efficacy and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) in conjunction with the meningococcal group C conjugate vaccine (MnCCV-CRM197) in infants and toddlers. This type of research is crucial for ensuring that our youngest members of society are protected from serious infections. A phase 3 randomized controlled trial, one of the gold standards in clinical research, was used to assess the immune response to these vaccines.

A Double Dose of Protection?

The results suggest that the PCV13 group exhibited lower geometric mean titers (GMTs) for the MenC SBA titer compared to the PCV7 group after both the second dose and the toddler dose. However, the proportion of infants achieving protective antibodies against MenC was similar between the two groups. This suggests that the lower GMTs may not translate to a clinically significant difference in the level of protection offered by PCV13. The study also found that PCV13 elicited a robust immune response against all 13 serotypes of pneumococcus, with a high percentage of subjects achieving protective antibody levels.

Protecting Our Little Ones, One Shot at a Time

This study provides further evidence supporting the safety and efficacy of PCV13, a crucial vaccine in protecting young children from serious pneumococcal infections. While the results suggest the potential for a slight decrease in the MenC antibody response when PCV13 is administered with MnCCV-CRM197, this is not a cause for alarm, as the majority of infants still achieved protective levels of antibodies. It's important to remember that vaccines are our desert oasis in the fight against infectious diseases, providing a vital shield of protection for our little ones.

Dr. Camel's Conclusion

Vaccines are like the protective camels of the desert, carrying our hopes and dreams for a healthier future. This study reaffirms the importance of PCV13 in protecting our little ones, and while the results suggest a slight nuance in the MenC antibody response, the overall message remains clear: vaccines are a vital tool for keeping our children safe and healthy.

Date :
  1. Date Completed 2014-06-02
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

24004465

DOI: Digital Object Identifier

10.1016/j.vaccine.2013.06.049

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.